Secondary progressive multiple sclerosis

This trial tests whether cladribine tablets change key immune cells and nerve damage markers in the spinal fluid of people with relapsing forms of multiple sclerosis. Participants take cladribine as prescribed and undergo up to two lumbar punctures to measure these biomarkers ove…

This study followed 134 adults in Italy with active secondary progressive multiple sclerosis who were prescribed siponimod (Mayzent) as part of their routine care. Over 36 months, researchers measured how many patients experienced a confirmed worsening of disability or cognitive …

This study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis. ECP is a procedure that filters a person's blood, treats it with light, and returns it to the body. The goal was to see if it is safe and if it can improve walking, hand …

This study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses they had per year. Researchers also tracked si…

This study tested an experimental drug called BIIB091, alone or combined with an approved MS drug (diroximel fumarate), in 127 people with relapsing multiple sclerosis. The goal was to check safety and see if it reduces brain inflammation on MRI scans. Participants took pills twi…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This pilot study tests whether a special MRI contrast agent called ferumoxytol can highlight areas of active inflammation in the brains of people with secondary progressive multiple sclerosis (SPMS). The goal is to see if this imaging method can distinguish chronic-active lesions…

This trial tests whether N-acetyl cysteine (NAC), an antioxidant supplement, can reduce fatigue in people with progressive multiple sclerosis. Participants take NAC or a placebo three times daily for four weeks, and researchers measure changes in fatigue scores and brain chemistr…

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…

This study looked at 46 people with progressive multiple sclerosis who have more weakness on one side of their body. Researchers used MRI scans to see how damage in the brain and spinal cord relates to muscle strength in each limb. The goal was to better understand what causes ph…

This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effect…

This completed observational study followed 367 people with relapsing-remitting or active secondary progressive multiple sclerosis who were taking Kesimpta for the first time. Researchers tracked side effects and how well the drug worked in everyday use. The goal was to gather re…

This study looked back at medical records of 606 people with secondary progressive multiple sclerosis (SPMS) in Russia who were taking siponimod. Researchers wanted to understand patient characteristics and how the drug was used in everyday practice. The study collected data from…